Trial
NCT01471964
Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Fox Chase Cancer Center
Collaborators
Millennium Pharmaceuticals, Inc.
Condition
Non-small Cell Lung Cancer Metastatic
Intervention
MLN8237 and Erlotinib
Why stopped
Phase I portion completed. Phase II will open pending amendment approval.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-05-17